These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 38249077)

  • 1. Novel Therapies in Glioblastoma Treatment: Review of Glioblastoma; Current Treatment Options; and Novel Oncolytic Viral Therapies.
    Shah S
    Med Sci (Basel); 2023 Dec; 12(1):. PubMed ID: 38249077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Developments in Glioblastoma Therapy: Oncolytic Viruses and Emerging Future Strategies.
    Hamad A; Yusubalieva GM; Baklaushev VP; Chumakov PM; Lipatova AV
    Viruses; 2023 Feb; 15(2):. PubMed ID: 36851761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraarterial delivery of virotherapy for glioblastoma.
    Srinivasan VM; Lang FF; Kan P
    Neurosurg Focus; 2021 Feb; 50(2):E7. PubMed ID: 33524944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic Viruses for Malignant Glioma: On the Verge of Success?
    Suryawanshi YR; Schulze AJ
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice.
    Shoaf ML; Desjardins A
    Neurotherapeutics; 2022 Oct; 19(6):1818-1831. PubMed ID: 35674873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic Virotherapy in Glioma Tumors.
    Rius-Rocabert S; García-Romero N; García A; Ayuso-Sacido A; Nistal-Villan E
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The oncolytic Newcastle disease virus as an effective immunotherapeutic strategy against glioblastoma.
    Cuoco JA; Rogers CM; Mittal S
    Neurosurg Focus; 2021 Feb; 50(2):E8. PubMed ID: 33524945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy.
    Volovat SR; Scripcariu DV; Vasilache IA; Stolniceanu CR; Volovat C; Augustin IG; Volovat CC; Ostafe MR; Andreea-Voichița SG; Bejusca-Vieriu T; Lungulescu CV; Sur D; Boboc D
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic immunovirotherapy for high-grade gliomas: A novel and an evolving therapeutic option.
    Asija S; Chatterjee A; Goda JS; Yadav S; Chekuri G; Purwar R
    Front Immunol; 2023; 14():1118246. PubMed ID: 37006286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas.
    Stergiopoulos GM; Concilio SC; Galanis E
    Curr Treat Options Oncol; 2024 Jul; 25(7):952-991. PubMed ID: 38896326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic viruses in lung cancer treatment: a review article.
    Sakhi H; Arabi M; Ghaemi A; Movafagh A; Sheikhpour M
    Immunotherapy; 2024 Feb; 16(2):75-97. PubMed ID: 38112057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glioblastoma Therapy: Rationale for a Mesenchymal Stem Cell-based Vehicle to Carry Recombinant Viruses.
    Ali S; Xia Q; Muhammad T; Liu L; Meng X; Bars-Cortina D; Khan AA; Huang Y; Dong L
    Stem Cell Rev Rep; 2022 Feb; 18(2):523-543. PubMed ID: 34319509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Efficacy of Oncolytic Viruses in Fighting Cancer: Recent Advances and Perspective.
    Garmaroudi GA; Karimi F; Naeini LG; Kokabian P; Givtaj N
    Oxid Med Cell Longev; 2022; 2022():3142306. PubMed ID: 35910836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic Zika Virus: New Option for Glioblastoma Treatment.
    Zhou C; Chen Q; Chen Y; Qin CF
    DNA Cell Biol; 2023 Jun; 42(6):267-273. PubMed ID: 36350682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of Oncolytic Virotherapy with Different Antitumor Approaches against Glioblastoma.
    Ageenko A; Vasileva N; Richter V; Kuligina E
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
    Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z
    Front Immunol; 2022; 13():1012806. PubMed ID: 36311790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy.
    Stepanenko AA; Sosnovtseva AO; Valikhov MP; Chernysheva AA; Abramova OV; Naumenko VA; Chekhonin VP
    Front Immunol; 2024; 15():1326757. PubMed ID: 38390330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
    Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Research Advances of Clinical Application of Oncolytic Viruses in Treatment of Gynecologic Cancers.
    Deng M; Wang Q
    Curr Cancer Drug Targets; 2023; 23(7):505-523. PubMed ID: 36824004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The two-faces of NK cells in oncolytic virotherapy.
    Marotel M; Hasim MS; Hagerman A; Ardolino M
    Cytokine Growth Factor Rev; 2020 Dec; 56():59-68. PubMed ID: 32586674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.